A randomized, controlled trial comparing insulin lispro with human soluble insulin in patients with Type 1 diabetes on intensified insulin therapy

Gale, E. A. M.

doi:10.1046/j.1464-5491.2000.00258.x

Cited by 99 publications

(13 citation statements)

References 17 publications

(17 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The reduction in postprandial blood glucose was also shown in other studies 19,20,23. The same is true for patients with type 2 diabetes mellitus, either as part of oral therapy or patients already on insulin therapy 19,24–26.…”

Section: Insulin Regular Versus Lisprosupporting

confidence: 76%

Cumulative clinical experience with use of insulin lispro: critical appraisal, role in therapy, and patient considerations

Uy¹,

Fogelfeld²,

Guerra³

2012

DMSO

View full text Add to dashboard Cite

We have now at our disposal the new rapid-acting insulin analogs, of which insulin lispro was the first to become commercially available. While the differences in pharmacokinetic and pharmacodynamic characteristics are indisputable, the clinical benefits attained by these changes have not been as clear. In the present review, we discuss the structure, pharmacology, and landmark studies related to insulin lispro. The clinical characteristics of insulin lispro are compared with those of insulin regular and other insulin analogs in different clinical situations. Also included are the aspects of quality of life and cost-effectiveness that may modify the modern practitioner’s decision to adopt one type of insulin over another.

show abstract

Section: Insulin Regular Versus Lisprosupporting

confidence: 76%

Cumulative clinical experience with use of insulin lispro: critical appraisal, role in therapy, and patient considerations

Uy¹,

Fogelfeld²,

Guerra³

2012

DMSO

View full text Add to dashboard Cite

show abstract

“…Rapid absorption of insulin lispro from subcutaneous site allows for a faster peak insulin concentration than is found with regular human insulin. [1617]…”

Section: Discussionmentioning

confidence: 99%

Efficacy of insulin lispro in improving glycemic control in gestational diabetes

Deepaklal

Joseph²,

Rekha³

et al. 2014

Indian J Endocr Metab

View full text Add to dashboard Cite

Aim:To assess the safety and efficacy of insulin lispro in improving glycemic control in patients with gestational diabetes.Materials and Methods:A retrospective observational study was conducted at a single center on 201 gestational women with diabetes. Subjects who received insulin lispro performed blood glucose self-monitoring and recorded the readings in the fasting state and 1 h after each meal. At each contact (in person or telephonic contact), the insulin dose was adjusted based on the readings measured. A total of 53 subjects also recorded glucose levels post-partum. Pregnancy and post-delivery glucose level and insulin requirements of these 53 patients were compared.Results:Analysis of glucose levels both fasting and post-prandial glucose levels revealed that after using insulin lispro, the number of episodes of post-prandial hyperglycemia (1 h plasma glucose >120 mg/dL) was minimal and so was the incidence of hypoglycemia. Hypoglycemia was defined as a blood sugar value of. There was neither any congenital abnormality except for a poorly formed pinna in the right ear of one baby nor any post-partum complications of note.Conclusion:Insulin lispro is an effective and safe treatment option in gestational diabetes.

show abstract

“…If both types of insulin are applied immediately before meals, in a blinded manner, no differences in treatment satisfaction, well-being, or HbA 1c were found (23). These results are supported by the recently published Cochrane Review, which also did not show any clinical benefit of short-acting insulin analogs in comparison with regular insulin in type 2 diabetes subjects (24).…”

Section: Discussionmentioning

confidence: 99%

Randomized Crossover Study to Examine the Necessity of an Injection-to-Meal Interval in Patients With Type 2 Diabetes and Human Insulin

et al. 2013

View full text Add to dashboard Cite

OBJECTIVEPatients with diabetes and insulin therapy with human insulin were usually instructed to use an interval of 20–30 min between the injection and meal. We examined the necessity of the injection-to-meal interval (IMI) in patients with type 2 diabetes mellitus (T2DM) and flexible insulin therapy with human insulin.RESEARCH DESIGN AND METHODSIn this randomized, open crossover trial, 100 patients with T2DM (47% men, mean age = 66.7 years) were randomized to the IMI first group (phase 1, IMI 20 min; phase 2, no IMI) or IMI last group (phase 1, no IMI; phase 2, IMI 20 min). The main outcome measures were HbA1c, blood glucose profile, incidence of hypoglycemia, quality of life, treatment satisfaction, and patient preference.RESULTSForty-nine patients were randomized to the IMI first group and 51 patients to the IMI last group. Omitting the IMI only slightly increases HbA1c (average intraindividual difference = 0.08% [95% CI 0.01–0.15]). Since the difference is not clinically relevant, a therapy without IMI is noninferior to its application (P < 0.001). In the secondary outcomes, the incidence of mild hypoglycemia also did not differ between no IMI and IMI significantly (mean of differences = −0.10, P = 0.493). No difference in the blood glucose profile of both groups was found. Treatment satisfaction increased markedly, by 8.08, if IMI was omitted (P < 0.001). The total score of the quality of life measure did not show differences between applying an IMI or not. Insulin therapy without IMI was preferred by 86.5% of patients (P < 0.001).CONCLUSIONSAn IMI for patients with T2DM and preprandial insulin therapy is not necessary.

show abstract

A randomized, controlled trial comparing insulin lispro with human soluble insulin in patients with Type 1 diabetes on intensified insulin therapy

Cited by 99 publications

References 17 publications

Cumulative clinical experience with use of insulin lispro: critical appraisal, role in therapy, and patient considerations

Cumulative clinical experience with use of insulin lispro: critical appraisal, role in therapy, and patient considerations

Efficacy of insulin lispro in improving glycemic control in gestational diabetes

Randomized Crossover Study to Examine the Necessity of an Injection-to-Meal Interval in Patients With Type 2 Diabetes and Human Insulin

Contact Info

Product

Resources

About